HCID 67262173, 화합물 → HCID 67256554, 화합물

HRID 1509199노트

반응식

HRID 1509199 반응식
[C:1]([O:5][C:6]([NH:8][C:9]1([C:13]2[CH:18]=[CH:17][C:16]([C:19]3[N:24]=[C:23]([N:25]([CH3:31])[CH2:26][C:27]([O:29]C)=O)[C:22]([N+:32]([O-])=O)=[CH:21][C:20]=3[C:35]3[CH:40]=[CH:39][CH:38]=[CH:37][CH:36]=3)=[CH:15][CH:14]=2)[CH2:12][CH2:11][CH2:10]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[H][H]>[Pd].C1COCC1>[C:1]([O:5][C:6](=[O:7])[NH:8][C:9]1([C:13]2[CH:14]=[CH:15][C:16]([C:19]3[C:20]([C:35]4[CH:40]=[CH:39][CH:38]=[CH:37][CH:36]=4)=[CH:21][C:22]4[NH:32][C:27](=[O:29])[CH2:26][N:25]([CH3:31])[C:23]=4[N:24]=3)=[CH:17][CH:18]=2)[CH2:10][CH2:11][CH2:12]1)([CH3:2])([CH3:3])[CH3:4]

참가 물질

5

반응물 2

HCID 67262173HCID 67262173, 화합물HCID 178418361HCID 178418361, 화합물

생성물 1

HCID 67256554HCID 67256554, 화합물수율 38.2%

시약·촉매·용매 2

HCID 23938Palladium촉매HCID 8028Tetrahydrofuran용매

실험 절차

In a glass autoclave were added methyl 2-((6-(4-(1-((tert-butoxycarbonyl)amino)cyclobutyl)phenyl)-3-nitro-5-phenylpyridin-2-yl)(methyl)amino)acetate (800 mg, 1.46 mmol) and 10% palladium on carbon (300 mg, 0.28 mmol) in THF (100 ml). The solution was hydrogenated at room temperature under 1.5 atm hydrogen for 20 hours. The reaction mixture was filtered through celite, then concentrated to dryness under reduced pressure. The residue was purified by Biotage chromatography (cyclohexane:ethyl acetate, gradient elution from 100:0 to 0:100) to afford the title compound (270 mg, 38%). 1H NMR (500 MHz, CDCl3): 7.35 (2H, d), 7.20-7.33 (5H, m), 7.15 (2H, d), 6.98 (1H, s), 5.05 (1H, br s), 4.11 (2H, s), 3.18 (3H, s), 2.20-2.70 (4H, br m), 2.00-2.14 (1H, m), 1.77-1.87 (1H, m), 1.10-1.50 (9H, br).

후처리

  1. filtrationThe reaction mixture was filtered through celite
  2. concentrationconcentrated to dryness under reduced pressure
  3. customThe residue was purified by Biotage chromatography (cyclohexane:ethyl acetate, gradient elution from 100:0 to 0:100)

출처 및 근거

ORD 기록
ord-9dd886e034d54a6bb91270d06c182ec3
출처 데이터셋
uspto-grants-2015_12
특허 번호
US09221838B2

반응 노트

불러오는 중…